Do you write news releases? And want help?
We offer free pre-publication review of releases. SEE MORE →
At the end of the day, what is important to most people is what exactly their individual risk might be, and the story offers no information on how well it evaluates that.
The news release buried the news that the combo pill offered modest improvement over standard treatment but didn’t reduce side effects significantly.
But, the story provided some data on the reported effectiveness of the app and cautioned it’s not foolproof.
A quarter of a percent reduced risk over a 15-year period seems speculative, not definitive.
Was it the hyperbaric treatment or something else that helped a patient profiled in a Philadelphia Inquirer story?
This release reads like an advertisement with pseudo-science added for flavor.
Conflicts of interest also weren’t mentioned–and they were notable in this case.
The release would have been more complete with a discussion on cost, harms and a better description of the evidence.
Multigene test may find risk for common diseases, but there’s no evidence it will make anyone healthier https://t.co/31lSMXLG2M
Delighted that @HealthNewsRevu have covered this Lancet study and the limitations 📖 There was lots of zealotry on show after this study. https://t.co/Cluh7HCdSe
Tips & Resources for Analyzing Health Care Claims
Podcast: Emergency docs highlight toxic health care myths
Podcast: The clear and present danger of too much health care
Podcast: The language of cancer